Eliminating TREX1 to restore immune control in triple-negative breast cancer

Active Project Grant Awarded Last action

Award ID
HT9425261E315
Recipient
Awarding agency
Obligated
$750,000

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 4% complete
Place of performance
New York, NY 10065, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded Sloan-Kettering Institute for Cancer Research $750,000 on October 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research eliminating TREX1 to restore immune control in triple-negative breast cancer. Performance extends through April 30, 2029, at the Institute's facility in New York, NY. The project is classified as a Project Grant, a form of assistance funding supporting basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research.

Quick answers

Who received award HT9425261E315?

HT9425261E315 was awarded to Sloan-Kettering Institute For Cancer Research by Defense Health Agency (Department of Defense) on October 1, 2026.

How much is award HT9425261E315 worth?

$750,000 has been obligated on HT9425261E315.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login